December 10, 2018: The United States Cardiovascular Drug Market displayed robust growth in assessment years. Cardiovascular disease is a fatal disease striking heart and related blood vessel disorders. They take on names as ischemic heart disease, dyslipedimia, stroke, thrombosis, atheroscelorosis, coronary artery diseases and likes. Cardiovascular diseases are diseases that strike the heart and block blood vessels. The various drugs available for treating cardiovascular diseases belong to a special class of medicines that target arrhythmia, myocardial infection and atherosclerosis. Anti-hypertensive drugs segment will hold dominant share of cardiovascular drugs market while anti-hyperlipidemcis segment slid up to top position to rake in market contribution in forecast period.

An enhanced population base that attracts high hospital visits on account of cardiovascular disease will demonstrate growth in hospital pharmacies segment. These disorders are linked to obesity, high cholesterol, smoking, excess alcohol and poor lifestyle. CVD is a major mortality source across the globe and more so with adults.

Antihypersensitive drugs hold dominance amongst CVD market share in terms of growth revenue and this stage of growth is primarily attributed by presence of multibillion dollar drugs such as Diovan and Benicar. Thrombolytic brands hold smaller fraction of total share as compared to antihypersensitive drugs but are projected to be fast movers forcing pace of growth of cardiovascular drugs market by revenue growth. North America accounts for largest share of market because of significant awareness of heart diseases and furthermore heart diseases striking people in America. Segmentation of United States Cardiovascular Drug Market by drug class includes antihyperlipidemics, antihypertensive, anti-coagulants, antifibrinolytic, antiarryhtmic.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Cardiovascular Drugs in these regions, from 2013 to 2025 (forecast).

United States Cardiovascular Drugs market competition by top manufacturers/players, with Cardiovascular Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

AstraZeneca

Pfizer Inc

Novartis AG

Merck

Bristol-Myers Squibb

Bayer AG

Sanofi

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche

Abbott Laboratories

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Anti Hyperlipidemics

Antihypertensive

Anti-Coagulants

Antifibrinolytic

Antiarrhythmic

Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.